Therapeutics for Equine Endocrine Disorders

• Autores: Andy E. Durham
• Localización: Veterinary Clinics of North America: Equine Practice: Equine Practice, ISSN-e 0749-0739, Vol. 33, Nº. 1, 2017, págs. 127-139
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Equine endocrine disease is commonly encountered by equine practitioners. Pituitary pars intermedia dysfunction (PPID) and equine metabolic syndrome (EMS) predominate. The most logical therapeutic approach in PPID uses dopamine agonists; pergolide mesylate is the most common. Bromocryptine and cabergoline are alternative drugs with similar actions. Drugs from other classes have a poor evidence basis, although cyproheptadine and trilostane might be considered. EMS requires management changes as the primary approach; reasonable justification for use of drugs such as levothyroxine and metformin may apply. Therapeutic options exist in rare cases of diabetes mellitus, diabetes insipidus, hyperthyroidism, and critical illness-related corticosteroid insufficiency.